Elevated expression of the prostaglandin synthase cyclooxygenase-2 (COX-2) is commonly observed in many chronic inflammatory diseases and cancer. However, the mechanisms allowing for pathogenic COX-2 overexpression are largely unknown. The gene for COX-2 (PTGS2) carries a common single-nucleotide polymorphism (SNP) at position 8473 (T8473C), in exon 10 that is associated with diseases in which COX-2 overexpression is a contributing factor. We demonstrate that the T8473C SNP resides within a region that targets COX-2 mRNA for degradation through microRNA-mediated regulation. miR-542-3p was identified to bind transcripts derived from the 8473T allele and promote mRNA decay. By contrast, the presence of the variant 8473C allele interfered with miR-542-3p binding, allowing for mRNA stabilization, and this effect was rescued using a mutated miR-542-3p at the respective 8473 site. Colon cancer cells and tissue displayed COX-2 mRNA levels that were dependent on T8473C allele dosage, and allele-specific expression of COX-2 was observed to be a contributing factor promoting COX-2 overexpression. These findings provide a novel molecular explanation underlying disease susceptibility associated with COX-2 T8473C SNP, and identify it as a potential marker for identifying cancer patients best served through selective COX-2 inhibition.
Introduction
Cyclooxygenase enzymes, COX-1 and COX-2, perform the rate-limiting step in the conversion of free arachidonic acid into prostaglandins and have distinct roles in physiologic and pathologic conditions (Wang and Dubois, 2010) . COX-1 (PTGS1) is the constitutively expressed isoform involved in gastric mucosa protection and maintenance of vascular tone. Normally absent in most cells, COX-2 (PTGS2) expression is rapidly induced by pro-inflammatory and growth-associated stimuli. Substantial evidence has shown unregulated COX-2 expression to be a contributing factor in many chronic diseases and cancer (Menter et al., 2010) . Numerous studies have demonstrated the benefit of inhibiting COX-2 activity with non-steroidal antiinflammatory drugs and COX-2 selective inhibitors. However, unwanted cardiovascular side effects associated with long-term COX-2 inhibition has limited their use as primary chemoprevention agents (Menter et al., 2010) .
Many genetic variants within the COX-2 gene have been identified and select polymorphisms have shown disease association. Several studies have identified the variant allele of one particular single-nucleotide polymorphism (SNP), T8473C (rs5275), to be associated with increased risk and/or NSAID responsiveness in a number of cancers where COX-2 overexpression has been observed (Campa et al., 2004; Ali et al., 2005; Siezen et al., 2005; Langsenlehner et al., 2006; Shen et al., 2006; Ferguson et al., 2008; Vogel et al., 2008; Gong et al., 2009; Ozhan et al., 2010) . The T8473C SNP is located in exon 10 which encodes the COX-2 3 0 -untranslated region (3 0 -UTR), and work from our group and others has identified the significance of this region in targeting COX-2 mRNA for posttranscriptional regulation (Young and Dixon, 2010) .
MicroRNAs (miRNAs) are small non-coding RNAs, B22 nucleotides in length, that primarily bind to the 3 0 -UTR of targeted transcripts and promote mRNA decay and translational suppression (Fabian et al., 2010) . Current work has established the critical role miRNAs have in regulating gene expression and the consequences of dysregulated miRNA expression (Croce, 2009 ). More recently, genetic polymorphisms in components of miRNA networks are being recognized as contributing factors in disease etiology (Ryan et al., 2010) . In this study, a common genetic alteration in the COX-2 3 0 -UTR was shown to impact specific miRNA activity allowing for COX-2 overexpression and disease association.
Results and discussion
miR-542-3p regulates COX-2 expression A bioinformatic approach was used to identify novel miRNAs that could target the COX-2 3 0 -UTR in the vicinity of the 8473 SNP. Using miRanda target prediction, miR-542-3p was predicted to bind the major allele 8473T with a minimum free energy of À20.29 kcal/mol. The functional significance of this potential miRNA:mRNA interaction was shown using HeLa cells stimulated with IL-1b to induce COX-2 expression, and then transfected with mature miR-542-3p. Northern and immunoblot analysis indicated that miR-542-3p was potent at inhibiting COX-2 mRNA and protein expression (Figures 1a-c) . This miRNA-dependent loss of COX-2 was reflected in B10-fold decreased PGE 2 synthesis, nearly to the extent observed with the COX-2 selective inhibitor NS-398 (Figure 1d ). The ability of miR-542-3p to attenuate PGE 2 synthesis was consistent with specific targeting of COX-2, as mRNA and protein expression of COX-1, mPGES-1, or 15-PGDH was not impacted by miR-542-3p (Supplementary Figures 1a-c) . miRNAs can regulate gene expression, both by influencing translation and by causing degradation of target mRNAs (Fabian et al., 2010) , and recent findings have implicated miRNA-mediated mRNA decay to be the predominant mechanism (Guo et al., 2010) . To determine if miR-542-3p controlled COX-2 expression through rapid mRNA decay, IL-1b-treated HeLa cells transfected with miR-542-3p were treated with actinomycin D to halt transcription and determine mRNA half-life (Figure 1e ). Consistent with previous results, IL-1b promoted COX-2 mRNA stabilization (Young et al., 2009) , whereas the presence of miR-542-3p promoted rapid decay leading to a >2-fold reduction in mRNA half-life.
To determine if the effect of miR-542-3p on COX-2 expression was mediated through direct association between miR-542-3p and COX-2 mRNA, miRNA ribonucleoprotein immunoprecipitation was performed to evaluate if miR-542-3p participated in recruiting COX-2 mRNA to the RNA-induced silencing complex (RISC) complex. IL-1b-treated HeLa cells were cotransfected with miR-542-3p or control miR, along with HA-tagged Argonaute-1 (Ago1) expression vector, a central component of RISC that directs miRNA-mRNA interaction (Fabian et al., 2010) . The association of COX-2 mRNA and miR-542-3p RNA with Ago1 was assayed by quantitative PCR in immunoprecipitates. As shown in Figures 2a and b , both COX-2 and miR-542-3p were highly enriched in the Ago1 samples, in which miR-542-3p was expressed. COX-2 and miR-542-3p were minimally detected in reactions using control miR, or in IPs using non-specific IgG. Furthermore, knockdown of Ago-1 negates the effect of miR-542-3p on COX-2 Figure 1 miR-542-3p regulates COX-2 expression. HeLa cells grown in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum were treated with 10 ng/ml IL-1b for 24 h to induce COX-2 expression, and then transfected for 48 h with 50 nM hsamiRNA-542-3p mature miRNA duplex, or random sequence control miRNA #2 (Ambion, Austin, TX, USA) using siQuest (Mirus, Madison, WI, USA). Non-transfected (NT) cells are indicated. (a) Total RNA was isolated using Trizol reagent (Invitrogen, Carlsbad, CA, USA). Northern blotting was performed as described (Dixon et al., 2000) , and probed with P 32 -labeled DNA probes for COX-2 and control actin. (b) cDNA was synthesized from 1 mg total RNA, and Taqman-based quantitative PCR reactions were performed to detect COX-2 mRNA. All values shown are first normalized to control glyceraldehydes 3-phosphate dehydrogenase (GAPDH) and then to the respective NT control. *P ¼ 0.0008. (c) COX-2 protein expression was evaluated by immunoblotting as described (Young et al., 2009) , using an anti-COX-2 antibody (160112; Cayman, Ann Arbor, MI, USA). Membranes were stripped and re-probed using bactin (Clone C4; MP Biomedicals, Solon, OH, USA). Detection and quantitation of blots were performed as described (Dixon et al., 2000) . Densitometry analysis was used to determine relative fold change in COX-2 intensity relative to the NT control and is listed underneath each representative sample. *P ¼ 0.0254. Data shown represents three experiments. (d) COX activity in IL-1b-stimulated HeLa cells transfected with miR-542-3p was assayed by determining PGE 2 levels in culture media by ELISA (R&D Systems, Minneapolis, MN, USA). Where indicated, cells were pre-treated with 10 mM NS-398 (Cayman) for 1 h, after which the media was removed and cultures were incubated for 20 min with serum-free media containing 10 mM arachidonic acid (Cayman). Relative PGE 2 levels were normalized to total protein levels and are an average of three experiments. *Po0.0001. (e) COX-2 mRNA half-life (t 1/2 ) was determined in HeLa cells stimulated with IL-1b for 24 h and then transfected with miR-542-3p (black circles) or control miR (open circles) for 48 h. Actinomycin D (5 mg/ml) was added to the growth medium and total RNA was prepared at the indicated time points. COX-2 mRNA decay was analyzed by real-time quantitative PCR using Taqman probes (Applied Biosystems) for detection of COX-2, and normalized to control GAPDH as described (Young et al., 2009 ).
T8473C SNP blocks miRNA regulation of COX-2 AE Moore et al mRNA stability (Figure 2c ). Taken together, these results indicate that miR-542-3p facilitates COX-2 mRNA association with RISC to promote rapid mRNA degradation.
A key 3 0 -UTR cis-acting element controlling COX-2 expression at the post-transcriptional level is the AU-rich element (ARE; Dixon et al., 2000) . Through its interaction with RNA-binding proteins, the ARE targets COX-2 mRNA for rapid decay and translational suppression (Young and Dixon, 2010) . Current work has shown that miRNAs can promote ARE-mediated mRNA decay through a mechanism directing recruitment of RNA degradation machinery to the ARE (Jing et al., 2005) . As the binding site for miR-542-3p is B350 nucleotides from the COX-2 ARE, we sought to determine if there was a functional interaction between these 3 0 -UTR elements. Luciferase reporter constructs bearing the full-length 8473T-containing COX-2 3 0 -UTR, or with the ARE deleted (Dixon et al., 2000) , were transfected along with miR-542-3p. As shown in Figure 2d , miR-542-3p was equally effective at inhibiting expression in the presence or absence of the ARE, indicating that the presence of the COX-2 ARE is not required for miR-542-3p function. A >2-fold reduction in luciferase mRNA was observed in the presence of miR-542-3p, consistent with miR-542-3p-dependent reduction in luciferase activity (Figure 2e (Abdelmohsen et al., 2008) ) ,using Lipofectamine Plus (Invitrogen) for 3 h. Media was changed and cells were transfected with either miR-542-3p or control miR, using siQuest for 24 h. Analysis of COX-2 mRNA (a) or miR-542-3p (b) with the RISC complex was performed as described , using a polyclonal anti-HA antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) or control IgG pre-coated to protein A/G PLUS agarose (Santa Cruz Biotechnology) to immunoprecipitate HA-tagged Ago1-containing RISC complex. Total RNA was isolated from immunoprecipitates using 1 ml Trizol per IP reaction. Taqman-based quantitative PCR reactions were performed to detect COX-2 mRNA or miR-542-3p as described . All values shown are normalized to the respective IgG control miRNA ribonucleoprotein immunoprecipitation reaction, and indicate the averages of three experiments. *P ¼ 0.0031; *P ¼ 0.0001. (c) HeLa cells treated with IL-1b for 24 h were initially transfected for 24 h with 50 nM siRNA for EIF2C1/Ago-1 or control siRNA (Ambion) using siQuest. Media was changed and cells were transfected with either miR-542-3p or control miR using siQuest for 24 h. Total RNA was isolated and Taqman-based quantitative PCR reactions were performed to detect COX-2 mRNA. *P ¼ 0.0007. (d) HeLa cells were transfected sequentially with luciferase (Luc) 3 0 -UTR reporter constructs (Dixon et al., 2000) containing no 3 0 -UTR, full-length 8473T-containing COX-2 3 0 -UTR (Luc þ 3 0 -UTR), or with the ARE deleted 3 0 -UTR (Luc þ DARE 3 0 -UTR), and miR-542-3p (black bars) or control miR (grey bars), using Lipofectamine Plus and siQuest, respectively. After 48 h, cells were lysed in reporter lysis buffer (Promega, Madison, WI, USA) and assayed using the Luciferase Assay System (Promega). Luciferase activity was normalized to total protein. All values shown are normalized to Luc expression in the respective control miR-transfected cells and indicate the averages of three experiments. *Pp0.02. (e) HeLa cells were transfected sequentially with Luc þ 3 0 -UTR reporter construct, and miR-542-3p (black bars) or control miR (grey bars). After 48 h, cells were harvested for total RNA, and Luc mRNA was analyzed by quantitative PCR using SYBR green PCR master mix (Applied Biosystems) and normalized to control glyceraldehydes 3-phosphate dehydrogenase. P ¼ 0.0064. Luc primers were sense 5 0 -ACGGATTACCAGGGATTTCAGTC-3 0 and antisense 5 0 -AGGCTCCTCAGAAACAGCTCTTC-3 0 .
T8473C SNP blocks miRNA regulation of COX-2 AE Moore et al interfere with miR-542-3p targeting of COX-2 (Supplementary Figure 2 ). Although these results differ from findings demonstrating the ability of HuR to rescue ARE-containing mRNAs from miRNA-mediated regulation, possibly by interfering with miRNA association with ARE-containing transcripts (Bhattacharyya et al., 2006) , they indicate that the ARE and miR-542-3p targeting site are functionally separate post-transcriptional regulatory elements that act independently to maintain tight control of COX-2 gene expression.
miR-542-3p targeting of COX-2 is dependent upon the T8473C SNP
Effective binding between an miRNA and its mRNA target are essential for miRNA-mediated regulation, and SNPs that exist within these miRNA target sites have potential to impact miRNA binding (Ryan et al., 2010) . Although the interaction between miR-542-3p and the wild-type 8473T allele is functional, the variant 8473C allele changes miR-542-3p binding with a predicted minimum free energy of À16.32 kcal/mol (Figure 3a ). To test if this polymorphism could alter miR-542-3p activity, 3 0 -UTR reporter constructs containing either 8473T or 8473C were cotransfected with miR-542-3p into HeLa cells. Comparable to the results in Figure 2b , miR-542-3p downregulates luciferase activity, approximately two-fold in the presence of the wild-type 8473T 3 0 -UTR (Figure 3b ). However, this inhibition was not observed with the 3 0 -UTR reporter bearing the variant 8473C SNP. To validate these results, miR-542-3p was mutated A-G at the COX-2 8473 site (labeled miR-542-3p Alt), such that it could bind the 8473C-containing 3 0 -UTR ( Figure 3a) . As shown in Figure 3b , this mutated miRNA did not impact expression from the 8473T 3 0 -UTR reporter, whereas miR-542-3p Alt was effective at inhibiting expression from the 8473C 3 0 -UTR reporter, further demonstrating that the context of T8473C SNP is a critical determinant of miR-542-3p function.
The results indicating that miR-542-3p promoted COX-2 mRNA decay (Figure 1e ) suggested that the presence of the variant 8473C allele may promote mRNA stabilization. This was evaluated by determining the half-life of luciferase mRNA containing each 8473
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Relative Luciferase Activity The wild-type COX-2 8473T 3 0 -UTR was mutated to incorporate the 8473C SNP using the QuickChange Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, CA, USA) and subcloned into the pcDNA3.1/Zeo/Luc vector (Dixon et al., 2000) . Luciferase 3 0 -UTR reporter constructs containing either full-length wild-type COX-2 8473T 3 0 -UTR or the variant 8473C 3 0 -UTR were cotransfected into HeLa cells with control miR (black bars), miR-542-3p (grey bars), miR-542-3p Alt (hatched bars) for 48 h. The hsa-miRNA-542-3p Alt miRNA was purchased from Ambion. Luciferase activity was assayed as described above. *Po0.05. (c) HeLa cells were stably transfected with reporter constructs Luc þ 8473T 3 0 -UTR (black circles) or Luc þ 8473C 3 0 -UTR (open circles) and selected in medium containing 150 mg/ml zeocin (Invitrogen) for 2-3 weeks. A polyclonal population of zeocin-resistant colonies were transfected with miR-542-3p for 48 h prior to treatment with 5 mg/ml actinomycin D at indicated times. Luc mRNA decay was analyzed by quantitative PCR using SYBR green PCR master mix and normalized to control glyceraldehydes 3-phosphate dehydrogenase. (d) HeLa cells were cotransfected with constructs expressing HAtagged Ago1, miR-542-3p, and either Luc þ 8473T 3 0 -UTR (labeled U, black bars) or Luc þ 8473C 3 0 -UTR (labeled C, grey bars) for 24 h. miRNA ribonucleoprotein immunoprecipitation of Ago1 was performed as described in Figure 2a , using SYBR green quantitative PCR detection of RISC-associated Luc mRNA. *P ¼ 0.003. T8473C SNP blocks miRNA regulation of COX-2 AE Moore et al 3 0 -UTR allele in the presence of miR-542-3p. As shown in Figure 3c , miR-542-3p promoted rapid luciferase mRNA decay from constructs bearing the wild-type 8473T 3 0 -UTR (t 1/2 ¼ 41 min), whereas stabilization was detected in mRNA bearing the variant 8473C 3 0 -UTR (t 1/2 ¼ 86 min). This two-fold difference in mRNA halflife was dependent on miR-542-3p targeting of the 8473T-containing 3 0 -UTR, as similar decay rates were observed for each construct when miR-542-3p was absent (data not shown).
Evidence indicating that deficient miR-542-3p binding to the 8473C-containing 3 0 -UTR was shown using miRNA ribonucleoprotein immunoprecipitation reactions. As shown in Figure 3d , luciferase mRNA bearing the wild-type 8473T 3 0 -UTR was associated in the Ago1/ RISC complex in the presence of miR-542-3p, whereas the 8473C SNP was sufficient to disrupt this association. Reactions using control miRNA or non-specific IgG did not display enrichment of luciferase mRNA in miRNA ribonucleoprotein immunoprecipitations, indicating that miR-542-3p binding and recruitment of Ago1-containing RISC complex is COX-2 T8473C-allele specific (Figure 3d and data not shown).
T8473C SNP disrupts miR-542-3p function to promote COX-2 overexpression COX-2 overexpression is commonly observed in colorectal cancer (CRC), and COX-2-dependent prostaglandin Figure 4 T8473C SNP disrupts miR-542-3p function to promote COX-2 expression in colon cancer. Human CRC lines HCA7, Moser, HT29 and LS174T were grown in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum, and were genotyped for T8473C SNP. Genomic DNA was extracted using QuickExtract (Epicentre, Madison, WI, USA), and T8473C SNP (rs5275) genotyping was conducted as described (Gong et al., 2009) . (a) Allelic mRNA discrimination assay was performed using Taqman PTGS2 T8473C SNP genotyping probes (Applied Biosystems) and were used to quantify wild-type (T) or variant (C) COX-2 mRNA allele expression using cDNA synthesized from total RNA. Quantitative analysis of allele expression was determined using fluorescence (Rn) values obtained from reactions containing VIC and FAM labeled probes to detect 8473T and 8473C alleles, respectively. The relative amount of each allele was determined using VIC Rn/(FAM Rn þ VIC Rn) and FAM Rn/(FAM Rn þ VIC Rn). For T/T homozygous samples, FAM Rn was below detection threshold and considered undetected. (b) CRC lines were transfected with miR-542-3p or control miR for 48 h, and analyzed by immunoblot for COX-2. The relative fold change in COX-2 protein relative to the NT control was accomplished by densitometry and is listed underneath each representative sample. HCA7 *P ¼ 0.0393, Moser *P ¼ 0.0233. (c) Moser (T/T, black circles) and HT29 (T/C, open circles) CRC cells were transfected with miR-542-3p for 48 h. COX-2 mRNA half-life was determined as described Figure 1d . (d) Human colon tumors were obtained from patients with CRC through the University of South Carolina Tumor Bank. Approximately 50 mg of tissue was used for DNA and mRNA analysis. Genomic DNA was extracted and genotyped for T8473C SNP. Left panel: Total RNA was isolated using Trizol and COX-2 mRNA levels were assayed by quantitative PCR using Taqman probes for detection of COX-2 and normalized to control glyceraldehydes 3-phosphate dehydrogenase. The data are represented as fold change in COX-2 levels using the lowest expressing T/T genotype tissue for normalization. *P ¼ 0.0002. Right panel: Protein was isolated from representative T/T, T/C and C/C tumor samples using Mammalian Protein Extraction Reagent (Thermo Scientific, Waltham, MA, USA), and analyzed by immunoblot for COX-2. Actin is shown as loading control.
T8473C SNP blocks miRNA regulation of COX-2 AE Moore et al synthesis promotes various facets of tumorigenesis leading to worse survival rates (Wang and Dubois, 2010) . To determine if a cause-and-effect relationship exists between T8473C SNP and miR-542-3p in CRC, cell lines were genotyped for T8473C SNP and evaluated for allelic COX-2 expression. The CRC cell lines HCA7 and Moser were of T/T genotype, whereas HT29 and LS174 T were heterozygotes (T/C) for the SNP; out of 10 CRC lines genotyped, no C/C homozygotes were identified. Allelic mRNA expression was accomplished using a Taqman-based allelic discrimination assay to measure transcript abundance. As shown in Figure 4a , only mRNA containing the 8473T SNP was detected from HCA7 and Moser cells. Interestingly, heterozygote cells HT29 and LS174T showed B90% of steady-state COX-2 mRNA to contain the 8473C SNP. This suggests that the mRNA derived from the 8473C-containing allele is inherently more stable than the 8473T-containing transcript owing to deficient miR-542-3p targeting.
To test this, CRC cells were transfected with miR-542-3p and evaluated for its effect on COX-2 expression. In T/T homozygote cells, miR-542-3p was able to downregulate B75% of COX-2 protein expression. By contrast, miR-542-3p was ineffective in attenuating COX-2 expression in T/C heterozygote cells (Figure 4b ). This effect appeared to be a result of deficient COX-2 mRNA decay mediated by miR-542-3p. As shown in Figure 4c , miR-542-3p promoted rapid mRNA decay in T/T homozygote Moser cells (t 1/2 ¼ 41 min), compared with T/C heterozygote HT29 cells (t 1/2 ¼ 77 min); similar half-lives of 67 and 83 min were observed in control miR-transfected Moser and HT29 cells, respectively. Although demonstrating the effect this SNP has on allelic COX-2 expression in CRC cells, these results indicate transcripts bearing the variant 8473C SNP to be inherently more stable and the underlying source of COX-2 overexpression.
It is conceivable that loss of miR-542-3p could occur during tumor development as observed with other tumor suppressor miRNAs (Croce, 2009 ) allowing for COX-2 overexpression. This was evaluated by assaying miR-542-3p expression in normal colon and tumor tissue along with CRC cell lines (Supplementary Figures  3a-c) . In both normal/tumor pairs and in CRC cells, the average miR-542-3p fold-change was not significant. Similarly, no correlation was observed between miR-542-3p levels and COX-2 mRNA levels in tumor tissue. These results are consistent with miR-542-3p expression in other tumor types (Volinia et al., 2006) , indicating that the T8473C SNP genetic variation could be a contributing factor impacting COX-2 levels. To assess this, CRC tumor samples were genotyped for T8473C SNP, and COX-2 levels were assayed. As shown in Figure 4d , there was a significant increase in both COX-2 mRNA and protein levels present in tumors that correlated with C allele dosage. With regard to tumor location, the 8743C allele frequency was greater in distal than proximal colon (60 versus 25%), which is consistent with COX-2 upregulation predominantly observed in distal colonic and rectal tumors (Dimberg et al., 1999; Nasir et al., 2004; Birkenkamp-Demtroder et al., 2005) . These results further demonstrate the significance the 8473T allele has in controlling COX-2 levels, and illustrate the profound effect the variant allele has in promoting COX-2 overexpression observed in CRC tumors.
A large amount of data from population studies and clinical trials demonstrate the efficacy of COX-2 selective inhibitors and non-steroidal anti-inflammatory drugs in reducing cancer risk (Menter et al., 2010) . However, an accurate measure of identifying patients most likely to receive the greatest chemopreventive benefit from COX-2 selective inhibitor-based therapy has been a limiting factor in that an incomplete understanding of the genetic causes associated with COX-2 overexpression currently exists. The results presented here describe the mechanism by which T8473C SNP functions in COX-2 regulation, and provides a molecular explanation to tumor susceptibility associated with this SNP. Through binding at the 8473 3 0 -UTR site, miR-542-3p targets COX-2 mRNA for decay, and the presence of the variant C-containing allele disrupted miRNA-mRNA interaction allowing for COX-2 overexpression. It is conceivable that this mechanism may impact expression of other miR-542-3p targets that contain SNPs within the miR-542-3p binding site (Supplementary Table 1) . By understanding the function of T8473C SNP, along with other 3 0 -UTR SNPs shown to affect miRNA activity (Nicoloso et al., 2010; Ryan et al., 2010) , these findings highlight the contribution of miRNA-mediated regulation of cancer-associated gene expression and supports their use as markers of risk and personalized therapy.
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